PGPeter X. Geng

Peter X. Geng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter X. Geng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BurnOmicsDB: A Curated and Standardized Database of Human Burn Injury Transcriptomics Across Tissues, Time Points, and Clinical Contexts

    by Peter X. Geng

    Public burn transcriptomic datasets remain difficult to compare because of differences in tissue source, study design, platform, annotation and statistical analysis. We developed BurnOmicsDB (https://peneapple.github.io/2026-BurnOmicsDB/), a curated and gene-centred web resource integrating six human burn-related Gene Expression Omnibus series comprising 1,013 public expression profiles. Dataset-specific quality control and differential-expression workflows were applied to 22 predefined contrasts across skin, wound margin, eschar, scar and blood, generating 448,735 standardized gene–contrast records. Gene identifiers and aliases were harmonized to support retrieval by official symbols, historical aliases, NCBI Gene IDs, Ensembl IDs and HGNC identifiers. Cross-tissue analysis showed that 564 of 1,444 genes with clear significant directions in both skin and blood exhibited opposite directions, highlighting the context dependence of burn-associated transcriptional responses. BurnOmicsDB enables code-free exploration and cross-study comparison of burn transcriptomic evidence for research and clinical reference, but is not intended for diagnosis or treatment decisions.

  • Open Access

    KRAS-Centred Network Analysis Prioritises Indirect Targets and Literature-Supported Drug-Repurposing Candidates

    by Peter X. Geng

    Direct pharmacological inhibition of KRAS remains constrained by mutation specificity, tumour heterogeneity and the emergence of resistance, motivating complementary strategies that target proteins associated with KRAS signalling. Here, we constructed a human KRAS-centred protein-association network and integrated network topology, functional enrichment, genomic-location analysis and target-level curation of approved drugs. The resulting network contained 21 proteins and 100 associations and comprised a canonical KRAS–RAF–ERK/PI3K signalling component together with a prominent calcium/calmodulin-associated module. Strict DrugBank curation identified 30 approved target–drug pairs involving six network proteins and 22 unique drugs. After excluding current or historical oncology agents and applying pharmacological-plausibility criteria, six conditional target–drug pairs involving four non-oncology drugs, fostamatinib, trifluoperazine, felodipine and nicardipine, were retained. A targeted literature review found supporting evidence for all four compounds in KRAS-relevant cancer settings. These compounds remain hypothesis-generating candidates rather than validated KRAS-directed therapies. This study provides a compact and reproducible strategy for translating a KRAS-associated protein network into a focused set of indirect target–drug hypotheses for subsequent computational and experimental evaluation.

  • Open Access

    Tripleknock: predicting lethal effect of three-gene knockout in bacteria by deep learning

    by Peter X. Geng, Jiaheng Hou, Jinyuan Guo, Xiaoqing Jiang, Huaiqiu Zhu

    Investigating the lethal effect of multi-gene knockout is essential for discovering novel antibiotics targets and metabolic engineering. Unlike single genes or gene pairs, three-gene combinations involve more intricate interactions, making experimental screening time-consuming. Computational methods, particularly Genome-scale metabolic Model (GEM)-based Flux Balance Analysis (FBA), requires constructing new GEMs from experimental data, limiting its use for new species. Moreover, using FBA for three-gene knockout screening could take several years. Therefore, a faster and GEMs-independent approach is needed to facilitate genome-wide three-gene knockout screening. Here, we introduce Tripleknock, for predicting the lethal effects of three-gene knockouts. Tripleknock was trained using whole-genome data from Escherichia coli K-12 MG1655, and three-gene knockout simulations using FBA. The model uses a threshold of 90% reduction in cell growth to define lethal effect as the prediction output. Compared to FBA, Tripleknock achieves predictions approximately 20 times faster, reaching an average cross-species F1 score of 0.77 on six pathogenic species within the Enterobacteriaceae family. For closely related species such as pathogenic E. coli and Shigella , Tripleknock reaches F1 scores exceeding 0.83. To our knowledge, Tripleknock is the first end-to-end model for predicting lethal effects of three-gene knockout in bacteria. Data availability: Tripleknock is publicly available at: https://github.com/Peneapple/Tripleknock

  • Open Access

    Developing Foundation Models for Predicting Viral Animal Host Range in Intelligent Surveillance

    by Jinyuan Guo, Qian Guo, Hengchuang Yin, Yilun Han, Peter X. Geng, Jiaheng Hou, Haoyu Zhang, Jie Tan, Mo Li, Yan Zhang, et al.

    Emerging human infectious viruses originating from animals continue to pose a persistent threat to global public health. Understanding the host range of animal viruses is crucial for identifying potential spillover pathways and mitigating the risk of future pandemics. Here, we present VirHRanger, a prediction method that integrates foundation models trained on viral genome and protein sequences, alongside genomic and protein compositional traits, viral phylogeny, and protein-protein interactions. To systematically predict the animal host range, VirHRanger incorporates host taxonomy-aware neural networks trained on a comprehensive collection of animal-virus associations spanning mammals, birds, and arthropods. Within a dataset of 4,006 virus species spanning 99 viral families, our model achieved robust performance with a micro-averaged AUROC of 0.938 across all host categories, demonstrating its effectiveness in capturing generalizable host signals from viral genetic data. On a dataset of 315 novel viruses, which are associated with key reservoir animal hosts and insect vectors, VirHRanger notably outperformed the homology-based method, exhibiting a strong generalizability to novel viruses. Furthermore, VirHRanger identified host range variations among closely related viruses within the Coronaviridae family and successfully predicted the ability of SARS-CoV-2 to infect humans and other animal hosts. These findings highlight the potential of VirHRanger to transform sequencing data into timely insights for disease control during the early stages of zoonotic outbreaks.


  • Open Access

    Characterizing the Binding Mechanism of Sparsentan to the Type-2 Angiotensin II Receptor Using AutoDock Vina

    by Peter X. Geng

    The angiotensin II type-2 receptor (AT2R) is known to have a significant impact on cardiovascular physiology, and the elucidation of its drug interactions is crucial for advancing therapeutic interventions. Sparsentan is an antagonist of angiotensin II, which has received FDA approval due to its demonstrated efficacy in ameliorating proteinuria. While sparsentan exhibits a preferential affinity for angiotensin II type-1 receptor (AT1R) and may primarily target it, DrugBank identifies it as a drug that targets AT2R. Present databases lack detailed structural data on the interaction mechanism between sparsentan and AT2R, leaving no definitive evidence to confirm or refute an interaction with AT2R. This study aimed to explore the potential for an interaction between sparsentan and AT2R. Molecular docking simulations were conducted using AutoDock Vina to predict the binding conformation. The docking parameters were meticulously optimized to ensure the accuracy and reliability of the simulation results. Subsequently, the most stable sparsentan-AT2R complex was determined. We identified four primary types of interactions at the binding site containing hydrogen bonds, hydrophobic interactions, π-cation interactions, and π-stacking, that are likely to contribute to the affinity of sparsentan for AT2R. Our study indicates that sparsentan may potentially interact with AT2R, our results may serve as a valuable reference for elucidating the mechanism of sparsentan action and for guiding the design of AT2R-targeted drugs.